Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


The purpose of this feasibility study is to determine if a new emerging technology called photoacoustic tomography (PAT) can be adapted for use in humans for the detection of chronic rheumatoid arthritis.

Study summary:

The objective of this proposal is to adapt photoacoustic tomography (PAT), a novel, nonionizing, noninvasive, laser-based technology, for structural and functional imaging of human peripheral joints affected by inflammatory arthritis. Combining the advantages of both light and ultrasound scanning, PAT holds promise to present objective optical information in subsurface joint tissues with high sensitivity and high spatial resolution. This could be of considerable help in the early detection of inflammatory joint diseases. PAT may also prove useful in further understanding the pathophysiology of these disorders and assisting with therapeutic decisions, including assessment of new pharmacological therapies.


Inclusion Criteria: - Men and women 18 years of age through age 60 can participate in this study. - Patients can participate in this study if they have had rheumatoid arthritis for more than 2 years and their rheumatologist has referred them to this study. - Patients can participate as a healthy volunteer with a known history of rheumatoid arthritis. Exclusion Criteria: - Patients, who have electrically, magnetically or mechanically activated implants such as heart pacemaker, magnetic surgical clips, prostheses or implanted neurological stimulator. - Pregnant patients. - Patients who is claustrophobic. - Patients with impaired renal function cannot participate in this study such as elevate creatinine clearance, patients on kidney dialysis etc. - Patients with shock hypotension or unstable low blood pressure. - Patients with Rhabdomyolysis. - Patients who have had a contrast enhanced (with gadolinium) MRA (magnetic resonance angiography)/ or MRI within the last 3 months. (Contrast is a medication injected into a vein during a imaging examination that helps produce clearer images/pictures).



Primary Contact:

Principal Investigator
Xueding Wang, Ph.D
University of Michigan

Backup Contact:


Location Contact:

Ann Arbor, Michigan 48109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.